Navigation Links
Lung Cancer Still Lowest in Federal Funding
Date:5/16/2008

Research Funding Per Death Drops More in 2007

WASHINGTON, May 16 /PRNewswire-USNewswire/ -- While lung cancer causes one in three cancer deaths, the National Cancer Institute (NCI) invested less than 5% of its $4.8 billion budget in lung cancer research in 2007, according to updated statistics issued by Lung Cancer Alliance (LCA) today.

The two other federal agencies with significant cancer research programs -- Centers for Disease Control and Prevention (CDC) and the Department of Defense (DOD) -- have no money earmarked for lung cancer in 2007.

Expressed in dollars per death, research funding through these three federal sources in 2007 totaled $23,754 for breast cancer, $11,959 for prostate cancer and $5,500 for colon cancer. Lung cancer research spending was $1,414 per death, a 23% drop from $1,829 in research funding per death in 2005.

LCA President & CEO Laurie Fenton Ambrose said these statistics paint a clear picture. "Despite lung cancer's enormous death toll, lung cancer research is still not a priority for our public health policy decision makers."

"The lack of public awareness of the statistics and the stigma of smoking has been a shield for those making these decisions, who also know that lung cancer leaves few survivors to demand more federal research funding money," she said.

"To this we say: No More," said Fenton Ambrose, whose Washington D.C. based national organization is the only one dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.

Lung cancer has the highest number of deaths and the highest death rate of all the cancers, taking more lives each year than breast, prostate, colon, kidney, and melanoma and liver cancers--combined.

"In addition, very few women even know that lung cancer will kill nearly twice as many women as breast cancer, that the number of women with lung cancer has soared or that one in every five women being diagnosed with lung cancer now has never smoked," said Fenton Ambrose.

Over 50% of new lung cancer patients are former smokers, many of whom quit decades ago. Another 10 to 15% have never smoked, with women non-smokers outnumbering men two to one.

"If women knew all these facts, they would be demanding that lung cancer research be funded at least at the same level as breast cancer research if not more," she said.

In 2007 research funding through NCI, CDC and DOD totaled $971,800,000 for breast cancer, $323,500,000 for prostate cancer, $287,000,000 for colon cancer and $226,900,000 for lung cancer.

In 2007 an estimated 52,180 people will die of colon cancer, 40,460 of breast cancer and 27,050 from prostate cancer. A total of 160,390 will die of lung cancer in 2007.

The 5-year survival rate for breast cancer is now 87%, for prostate cancer 99% and for colon cancer 64%. The 5-year survival rate for lung cancer is 15%.

Statistical report attached and can be viewed at http://www.lungcanceralliance.org.

Lung Cancer Alliance (http://www.lungcanceralliance.org) is the only national non-profit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Kay Cofrancesco

202-463-2080

kay@lungcanceralliance.org


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Partnerships Effective Communicators of Cancer Advances
2. Not All Colon Cancer Patients Need Chemotherapy: Study
3. National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling:
4. Bone drug could help prevent the spread of breast cancer
5. Childhood Cancer Survivors Prone to Early Heart Trouble
6. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
7. Cancer patients quality of life directly relates to their survival
8. Blood Test Helps Docs Assess Breast Cancer Treatment
9. Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients
10. Novel enzyme inhibitor paves way for new cancer drug
11. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology: